Marco Genua

Marco Genua

Auto-generated profile, based on publicly available information

Marco Genua

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Nature
Verified
Journal Article
Closed access
PDF file
NCNicoletta Caronni
Nicoletta Caronni
FTFederica La Terza
Federica La Terza
FVFrancesco M. Vittoria
Francesco M. Vittoria
GBGiulia Barbiera
Giulia Barbiera
LMLuca Mezzanzanica
Luca Mezzanzanica
RORenato Ostuni
Renato Ostuni

22 September 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
EMElisa Montaldo
Elisa Montaldo
ELEleonora Lusito
Eleonora Lusito
VBValentina Bianchessi
Valentina Bianchessi
NCNicoletta Caronni
Nicoletta Caronni
SSSerena Scala
Serena Scala
RORenato Ostuni
Renato Ostuni

8 August 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SDSilvia D’alessio
Silvia D’alessio
CCCarmen Correale
Carmen Correale
CTCarlotta Tacconi
Carlotta Tacconi
AGAlessandro Gandelli
Alessandro Gandelli
GPGiovanni Pietrogrande
Giovanni Pietrogrande
SDSilvio Danese
Silvio Danese
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory bowel diseases (IBDs) of unknown etiology that are associated with an aberrant mucosal immune response. Neoangiogenesis and vascular injury are observed in IBD along with increased lymphangiogenesis. While the pathogenic role of angiogenesis in IBD is well characterized, it is not clear how or if increased lymphangiogenesis promotes disease. Here, we determined that enhancing lymphangiogenesis and lymphatic function reduces experimental IBD. Specifically, we demonstrated that adenoviral induction of prolymphangiogenic factor VEGF-C provides marked protection against the development of acute and chronic colitis in 2 different animal models. VEGF-C–dependent protection was observed in combination with increased inflammatory cell mobilization and bacterial antigen clearance from the inflamed colon to the draining lymph nodes. Moreover, we found that the VEGF-C/VEGFR3 pathway regulates macrophage (MΦ) plasticity and activation both in cultured MΦs and in vivo, imparting a hybrid M1-M2 phenotype. The protective function of VEGF-C was meditated by the so-called resolving MΦs during chronic experimental colitis in a STAT6-dependent manner. Together, these findings shed light on the contribution of lymphatics to the pathogenesis of gut inflammation and suggest that correction of defective lymphatic function with VEGF-C has potential as a therapeutic strategy for IBD.

1 July 2015 in Gastroenterology
Verified
Journal Article
Closed access
ESEmanuela Sala
Emanuela Sala
MGMarco Genua
Marco Genua
LPLuciana Petti
Luciana Petti
Achille AnselmoAchille Anselmo
Achille Anselmo
VAVincenzo Arena
Vincenzo Arena
SVStefania vetrano
Stefania vetrano

13 March 2017 in Nature Immunology
Verified
Journal Article
Open access
PDF file
VPViviana Piccolo
Viviana Piccolo
ACAlessia Curina
Alessia Curina
MGMarco Genua
Marco Genua
SGSerena Maria Ghisletti
Serena Maria Ghisletti
MSMarta Simonatto
Marta Simonatto
GNGioacchino Natoli
Gioacchino Natoli
Natoli and colleagues reveal the epigenomic and transcriptional bases for gene-specific cross-repression of the cytokines IFN-γ and IL-4 in macrophages. Stimulation of macrophages with interferon-γ (IFN-γ) and interleukin 4 (IL-4) triggers distinct and opposing activation programs. During mixed infections or cancer, macrophages are often exposed to both cytokines, but how these two programs influence each other remains unclear. We found that IFN-γ and IL-4 mutually inhibited the epigenomic and transcriptional changes induced by each cytokine alone. Computational and functional analyses revealed the genomic bases for gene-specific cross-repression. For instance, while binding motifs for the transcription factors STAT1 and IRF1 were associated with robust and IL-4-resistant responses to IFN-γ, their coexistence with binding sites for auxiliary transcription factors such as AP-1 generated vulnerability to IL-4-mediated inhibition. These data provide a core mechanistic framework for the integration of signals that control macrophage activation in complex environmental conditions.

1 October 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
RIRenato V. Iozzo
Renato V. Iozzo
SBSimone Buraschi
Simone Buraschi
MGMarco Genua
Marco Genua
SXShi-Qiong Xu
Shi-Qiong Xu
CSCharalambos C. Solomides
Charalambos C. Solomides
Andrea MorrioneAndrea Morrione
Andrea Morrione
We have recently discovered that the insulin-like growth factor receptor I (IGF-IR) is up-regulated in human invasive bladder cancer and promotes migration and invasion of transformed urothelial cells. The proteoglycan decorin, a key component of the tumor stroma, can positively regulate the IGF-IR system in normal cells. However, there are no available data on the role of decorin in modulating IGF-IR activity in transformed cells or in tumor models. Here we show that the expression of decorin inversely correlated with IGF-IR expression in low and high grade bladder cancers (n = 20 each). Decorin bound with high affinity IGF-IR and IGF-I at distinct sites and negatively regulated IGF-IR activity in urothelial cancer cells. Nanomolar concentrations of decorin promoted down-regulation of IRS-1, one of the critical proteins of the IGF-IR pathway, and attenuated IGF-I-dependent activation of Akt and MAPK. This led to decorin-evoked inhibition of migration and invasion upon IGF-I stimulation. Notably, decorin did not cause down-regulation of the IGF-IR in bladder, breast, and squamous carcinoma cells. This indicates that decorin action on the IGF-IR differs from its known activity on other receptor tyrosine kinases such as the EGF receptor and Met. Our results provide a novel mechanism for decorin in negatively modulating both IGF-I and its receptor. Thus, decorin loss may contribute to increased IGF-IR activity in the progression of bladder cancer and perhaps other forms of cancer where IGF-IR plays a role.